AZ's Dapagliflozin Impresses In Topline Phase III Heart Failure Study
Executive Summary
AstraZeneca’s SGLT2 inhibitor has grabbed attention for its potential role in chronic heart failure patients, with or without type 2 diabetes, following initial results from the DAPA-HF study.
You may also be interested in...
Lilly/BI's Jardiance Scores A Win In Heart Failure Where Rivals Have Not
A Phase III trial in heart failure with preserved ejection fraction showed a benefit, which could result in a broad heart failure label for the SGLT2 inhibitor.
Novartis’s Entresto PARAGON-HF Miss Puts Large Commercial Opportunity At Risk
Entresto has narrowly failed to hit the primary endpoint in a Phase III trial in heart failure with preserved ejection fraction, a potentially lucrative indication with no approved treatments.
BI Bets On Expanding Jardiance As Diabetes Drug Sales Soar
The German major believes its drug will remain the biggest-selling SGLT-2 inhibitor boosted by expanded heart and renal disease approvals.